Nanotherapeutic Colloidal Metal Compositions and Methods
The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor, a stealth agent such as polyethylene glycol, and one or more diagnostic or therapeutic agents for delivery. The invention also comprises methods and compositions for making such nanotherapeutic compositions and for the treatment of cancer.
1 . A nanotherapeutic vector composition, comprising a nanoparticle platform, a stealth agent and one more more active agents, wherein the stealth agent and one or more active agents are bound to the nanoparticle platform.
2 . The nanotherapeutic vector composition of claim 1 , wherein the nanoparticle platform is selected from the group consisting of; a colloidal metal, a nanoshell, a nanorod, a quantum dot, a nanocluster, a liposome, a dendrimer, a metal-liposome particle, a metal-dendrimer nanohybrid, and a nanotube.
3 . The nanotherapeutic vector composition of claim 2 , wherein the nanoparticle platform is a colloidal metal and wherein the colloidal metal comprises a material selected from the group consisting of; gold, silver, silica, and iron.
4 . The nanotherpeutic vector composition of claim 3 , wherein the colloidal metal is colloidal gold.
5 . The nanotherapeutic vector composition of claim 1 , wherein the stealth agent is selected from the group consisting of; polyethylene glycol (PEG), hyroxyethyl starch (HES/HAES), PolyPEG®, rPEG, branched aminated PEGs, polyoxypropylene polymers, block or triblock copolymers comprising polyoxyethylene/polyoxypropylene/polyoxyethylene blocks, and methacrylamide polymers.
6 . The nanotherapeutic vector composition of claim 5 , wherein the stealth agent is a branched aminated PEG.
7 . The nanotherapeutic vector composition of claim 6 , wherein the branched aminated PEG is a 4 arm or 6 arm branched aminated PEG.
8 . The nanotherapeutic vector composition of claim 5 , wherein the stealth agent is a methacrylamide polymer.
9 . The nanotherapeutic vector composition of claim 8 , wherein the methacrylamide polymer is a N-(2-hydroxypropyl)methacrylamide polymer.
10 . The vector composition of claim 1 , wherein the one or more active agents is tumor necrosis factor alpha (TNF) and paclitaxel.
11 . The vector composition of claim 1 , further comprising a targeting ligand.
12 . A nanotherapeutic vector composition comprising one or more functionalized polymers attached to a nanoparticle platform, wherein the functionalized polymer comprises one or more active agents attached to a polymer backbone.
13 . The nanotherapeutic vector composition of claim 12 , wherein the functionalized polymer comprises a methacrylamide backbone.
14 . The nanotherapeutic vector composition of claim 13 , wherein the methacrylamide backbone comprises N-(2-hydroxypropyl)methacrylamide monomers, wherein a therapeutic agent, diagnostic agent, or targeting ligand is attached to each monomer.
15 . The nanotherapeutic vector composition of claim 14 , wherein paclitaxel is attached the methacrylamide backbone.
16 . The nanotherapeutic vector composition of claim 14 , wherein paclitaxel and TNF are attached to the methacrylamide backbone.
17 . The nanotherapeutic vector composition of claim 14 , wherein a diagnostic agent is attached to the methacrylamide backbone.
18 . The nanotherapeutic vector composition of claim 17 , wherein the diagnostic agent is chelating agent for an imaging radionuclide.
19 . The nanotherapeutic vector composition of claim 18 , wherein the chelating agent is 99m Tc.
20 . The nanotherapeutic vector composition of claim 14 , wherein a chelating agent for a therapeutic nucleotide is attached to the methacrylamide backbone.
21 . The nanotherapeutic vector composition of claim 18 , wherein the therapeutic radionuclide is 90 Y.
22 . The nanotherapeutic vector composition of claim 14 , wherein the functionalized polymer further comprises a stealth domain comprising unmodified methacrylamide monomers.